Nurix Stock Today

NRIX
 Stock
  

USD 11.71  0.36  3.17%   

Market Performance
0 of 100
Odds Of Distress
Less than 24
Nurix Therapeutics is trading at 11.71 as of the 30th of November 2022; that is 3.17 percent up since the beginning of the trading day. The stock's open price was 11.35. Nurix Therapeutics has about a 24 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Nurix Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of June 2022 and ending today, the 30th of November 2022. Click here to learn more.
Fiscal Year End
November
IPO Date
24th of July 2020
Category
Healthcare
ISIN
US67080M1036
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company was incorporated in 2009 and is headquartered in San Francisco, California. The company has 44.61 M outstanding shares of which 4.97 M shares are now shorted by private and institutional investors with about 10.92 trading days to cover. More on Nurix Therapeutics

Moving against Nurix Therapeutics

-0.71AZPNAspen Technology Downward RallyPairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Nurix Therapeutics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Nurix Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Nurix Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Nurix Therapeutics generated a negative expected return over the last 90 days
Nurix Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 39.24 M. Net Loss for the year was (171.34 M) with loss before overhead, payroll, taxes, and interest of (86.68 M).
Nurix Therapeutics currently holds about 344.48 M in cash with (152.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.31.
Latest headline from news.google.com: Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies - Marketscreener.com
Average Analyst Recommendation
Analysts covering Nurix Therapeutics report their recommendations after researching Nurix Therapeutics' financial statements, talking to executives and customers, or listening in on Nurix Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Nurix Therapeutics. The Nurix consensus assessment is calculated by taking the average forecast from all of the analysts covering Nurix Therapeutics.
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Nurix Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldUndervalued
Nurix Therapeutics (NRIX) is traded on NASDAQ Exchange in USA and employs 242 people. The company currently falls under 'Small-Cap' category with current market capitalization of 530.44 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Nurix Therapeutics's market, we take the total number of its shares issued and multiply it by Nurix Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Nurix Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 44.61 M outstanding shares of which 4.97 M shares are now shorted by private and institutional investors with about 10.92 trading days to cover. Nurix Therapeutics currently holds about 344.48 M in cash with (152.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.31.
Check Nurix Therapeutics Probability Of Bankruptcy
Ownership
Nurix Therapeutics maintains a total of fourty-four million six hundred ten thousand outstanding shares. The majority of Nurix Therapeutics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Nurix Therapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Nurix Therapeutics. Please pay attention to any change in the institutional holdings of Nurix Therapeutics as this could imply that something significant has changed or about to change at the company. Also note that almost two million two hundred thirty thousand five hundred invesors are currently shorting Nurix Therapeutics expressing very little confidence in its future performance.

Ownership Allocation (%)

Check Nurix Ownership Details

Nurix Stock Price Odds Analysis

Based on a normal probability distribution, the odds of Nurix Therapeutics jumping above the current price in 90 days from now is about 81.3%. The Nurix Therapeutics probability density function shows the probability of Nurix Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.8323. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Nurix Therapeutics will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Nurix Therapeutics is significantly underperforming DOW.
  Odds Below 11.71HorizonTargetOdds Above 11.71
18.62%90 days
 11.71 
81.30%
Based on a normal probability distribution, the odds of Nurix Therapeutics to move above the current price in 90 days from now is about 81.3 (This Nurix Therapeutics probability density function shows the probability of Nurix Stock to fall within a particular range of prices over 90 days) .

Nurix Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Nurix Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Nurix Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Nurix Therapeutics' value.
InstituionSecurity TypeTotal SharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares5.1 K65 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares5.1 K72 K
View Nurix Therapeutics Diagnostics

Nurix Therapeutics Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Nurix Therapeutics market risk premium is the additional return an investor will receive from holding Nurix Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Nurix Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Nurix Therapeutics' alpha and beta are two of the key measurements used to evaluate Nurix Therapeutics' performance over the market, the standard measures of volatility play an important role as well.

Nurix Stock Against Markets

Picking the right benchmark for Nurix Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Nurix Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Nurix Therapeutics is critical whether you are bullish or bearish towards Nurix Therapeutics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Nurix Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Volatility Analysis Now

   

Volatility Analysis

Get historical volatility and risk analysis based on latest market data
All  Next Launch Module

Invested in Nurix Therapeutics?

The danger of trading Nurix Therapeutics is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Nurix Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Nurix Therapeutics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Nurix Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additionally, see Correlation Analysis. You can also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for analysis

When running Nurix Therapeutics price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Is Nurix Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nurix Therapeutics. If investors know Nurix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nurix Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
535.1 M
Quarterly Revenue Growth YOY
0.053
Return On Assets
(0.23) 
Return On Equity
(0.48) 
The market value of Nurix Therapeutics is measured differently than its book value, which is the value of Nurix that is recorded on the company's balance sheet. Investors also form their own opinion of Nurix Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Nurix Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nurix Therapeutics' market value can be influenced by many factors that don't directly affect Nurix Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nurix Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Nurix Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nurix Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.